AbbVie (NYSE:ABBV) Trading 1.4% Higher – What’s Next?

AbbVie Inc. (NYSE:ABBV) shot up 1.4% during trading on Friday . The stock traded as high as $266.84 and last traded at $265.62. Approximately 5,132,681 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 6,851,311 shares. The stock had previously closed at $261.83.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New lung-cancer data supports AbbVie’s long-term growth strategy. At the 2026 World Conference on Lung Cancer, AbbVie presented clinical, translational and real-world data for investigational programs including ABBV-1480, telisotuzumab adizutecan and ABBV-706 across non-small cell and small cell lung cancer. The updates highlight potential future oncology revenue sources beyond the company’s established immunology portfolio. AbbVie WCLC 2026 announcement
• Positive Sentiment: AbbVie is broadening its aesthetics pipeline. The company has initiated a Phase 2 study evaluating a treatment for forehead lines, adding another potential product to its aesthetics franchise and reinforcing efforts to diversify growth. AbbVie aesthetics pipeline update
• Neutral Sentiment: AbbVie’s relatively low market correlation reflects its defensive pharmaceutical revenue base. Investor performance is driven more by product demand, reimbursement and payer dynamics than by broad equity-market movements. This may help explain the stock’s resilience, but the article does not identify a new earnings catalyst. What Moves AbbVie Stock
• Neutral Sentiment: AbbVie recently reported quarterly EPS and revenue above consensus, with revenue rising 10.2% year over year, and guided to third-quarter EPS of $3.84–$3.88. Analysts’ average price target of $275.73 remains above the current trading level, although the stock’s elevated valuation raises expectations. AbbVie stock and earnings information
• Negative Sentiment: An early end to a long-term emraclidine schizophrenia study introduces uncertainty. Investors may question the implications for AbbVie’s neuroscience pipeline and the program’s development prospects until the company provides additional details. AbbVie emraclidine study update
• Negative Sentiment: An executive vice president sold approximately $8.18 million of ABBV shares, reducing his position by about 30.5%. The sale may weigh modestly on sentiment, although insider transactions can reflect personal financial planning rather than a change in business outlook. AbbVie insider sale

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of recent research reports. HSBC reiterated a “buy” rating and set a $300.00 price objective on shares of AbbVie in a research note on Monday, July 6th. Guggenheim raised their target price on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Citigroup upped their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Finally, Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a research note on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $275.95.

AbbVie Stock Performance

The firm has a market cap of $469.29 billion, a P/E ratio of 75.03, a P/E/G ratio of 0.88 and a beta of 0.30. The firm’s fifty day simple moving average is $248.48 and its 200 day simple moving average is $227.49.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the previous year, the firm posted $2.97 earnings per share. The business’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts predict that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio is 195.48%.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On AbbVie

A number of hedge funds have recently bought and sold shares of ABBV. Brighton Jones LLC lifted its stake in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares during the period. Schnieders Capital Management LLC. increased its position in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after purchasing an additional 789 shares during the last quarter. Ieq Capital LLC increased its position in shares of AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock valued at $22,281,000 after purchasing an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC raised its holdings in AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after buying an additional 612,702 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.